Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Assertio Therapeutics stock
Learn how to easily invest in Assertio Therapeutics stock.
Assertio Therapeutics is a drug manufacturers-specialty & generic business based in the US. Assertio Therapeutics shares (ASRT) are listed on the NASDAQ and all prices are listed in US Dollars. Assertio Therapeutics employs 19 staff and has a trailing 12-month revenue of around $139.2 million.
How to buy Assertio Therapeutics stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – ASRT. It's that simple.
- Trade stocks and ETFs for $0 and no annual fee
- Minimum deposit of $10 required
- Get $10 when you sign up and deposit $100
- Commission-free trading
- Commission-free crypto
- No minimum account balance
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
What's in this guide?
Assertio Therapeutics stock price (NASDAQ: ASRT)Use our graph to track the performance of ASRT stocks over time.
Assertio Therapeutics shares at a glance
|Latest market close||$4.29|
|52-week range||$1.86 - $4.44|
|50-day moving average||$3.46|
|200-day moving average||$2.97|
|Wall St. target price||$7.19|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$0.54|
Buy Assertio Therapeutics stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Assertio Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Assertio Therapeutics price performance over time
|1 week (2023-01-19)||15.01%|
|1 month (2022-12-23)||5.15%|
|3 months (2022-10-26)||75.10%|
|6 months (2022-07-26)||22.57%|
|1 year (2022-01-26)||88.16%|
|2 years (2021-01-26)||518.96%|
|3 years (2020-01-24)||283.04%|
|5 years (2018-01-26)||7.81|
Is Assertio Therapeutics stock undervalued or overvalued?
Valuing Assertio Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Assertio Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Assertio Therapeutics's P/E ratio
Assertio Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 7x. In other words, Assertio Therapeutics shares trade at around 7x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Assertio Therapeutics's PEG ratio
Assertio Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.6155. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Assertio Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Assertio Therapeutics's EBITDA
Assertio Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $86.8 million.
The EBITDA is a measure of a Assertio Therapeutics's overall financial performance and is widely used to measure a its profitability.
Assertio Therapeutics financials
|Revenue TTM||$139.2 million|
|Operating margin TTM||39.08%|
|Gross profit TTM||$95.8 million|
|Return on assets TTM||10.92%|
|Return on equity TTM||22.16%|
|Market capitalisation||$171 million|
TTM: trailing 12 months
Assertio Therapeutics share dividends
We're not expecting Assertio Therapeutics to pay a dividend over the next 12 months.
Have Assertio Therapeutics's shares ever split?
Assertio Therapeutics's shares were split on a 1:4 basis on 17 May 2021. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Assertio Therapeutics shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Assertio Therapeutics shares which in turn could have impacted Assertio Therapeutics's share price.
Assertio Therapeutics share price volatility
Over the last 12 months, Assertio Therapeutics's shares have ranged in value from as little as $1.86 up to $4.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Assertio Therapeutics's is 1.5051. This would suggest that Assertio Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Assertio Therapeutics overview
Assertio Holdings, Inc. , a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020.
Assertio Therapeutics in the news
Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
Assertio Announces Partnership with the Lennox-Gastaut Syndrome (LGS) Foundation
Frequently asked questionsWhat percentage of Assertio Therapeutics is owned by insiders or institutions?
Currently 1.78% of Assertio Therapeutics shares are held by insiders and 35.999% by institutions. How many people work for Assertio Therapeutics?
Latest data suggests 19 work at Assertio Therapeutics. When does the fiscal year end for Assertio Therapeutics?
Assertio Therapeutics's fiscal year ends in December. Where is Assertio Therapeutics based?
Assertio Therapeutics's address is: 100 South Saunders Road, Lake Forest, IL, United States, 60045 What is Assertio Therapeutics's ISIN number?
Assertio Therapeutics's international securities identification number is: US04546C2052 What is Assertio Therapeutics's CUSIP number?
Assertio Therapeutics's Committee on Uniform Securities Identification Procedures number is: 04545L107
More guides on Finder
How to buy TXO Energy (TXO) stock when it goes public
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock when it goes public
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert